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Abstract 
Background and Purpose 
Identifying the causal pathogens of pneumonia complicating stroke is challenging and 
antibiotics used are often broad spectrum, without recourse to the microbiological etiology.  
We aimed to review existing literature to identify organisms responsible for pneumonia 
complicating stroke, prior to developing a consensus based approach to antibiotic treatment.  
Methods 
A systematic literature review of multiple electronic databases using pre-defined search 
criteria was undertaken, in accordance with Cochrane and PRISMA guidance. Published 
studies of hospitalized adults with ischemic stroke (IS), intracerebral hemorrhage (ICH), or 
both, which identified microbiological etiologies for pneumonia complicating stroke up to 
1
st
January 2017, were considered. Analysis included summary statistics and random-effects 
meta-analysis where appropriate. 
Results 
15 studies (40% IS, 60% IS and ICH) involving 7968 patients were included. Reported 
occurrence of pneumonia varied considerably between studies (2% to 63%) with a pooled 
frequency of 23% (95% Confidence Interval, 14%-34%; I
2
=99%). Where reported (60%), the 
majority of pneumonia occurred within 1 week of stroke (78%). Reported frequency of 
positive culture data (15% to 88%) varied widely. When isolated, aerobic Gram negative 
bacilli (AGNB, 38%) and Gram positive cocci (GPC, 16%) were most frequently cultured; 
commonly isolated organisms included Enterobacteriaceae (21.8%: Klebsiella pneumoniae, 
12.8% and Escherichia coli, 9%), Staphylococcus aureus (10.1%), Pseudomonas aeruginosa 
(6%), Acinetobater baumanii (4.6%) and Streptococcus pneumoniae (3.5%). Sputum was 
most commonly used to identify pathogens, in isolation (40%) or in conjunction with tracheal 
aspirate (15%) or blood culture (20%). 
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Conclusions 
Whilst analysis was limited by small and heterogeneous study populations, limiting 
determination of microbiological causality, this review suggests AGNB and GPC are 
frequently associated with pneumonia complicating stroke. This supports the need for 
appropriately designed studies to determine microbial etiology and a consensus based 
approach in antibiotic usage and further targeted antibiotic treatment trials for enhanced 
antibiotic stewardship. 
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Introduction 
Pneumonia complicating stroke occurs frequently, independently increasing mortality 3-fold 
and increasing hospitalisation costs, length of stay and likelihood of poor outcome in 
survivors. 
1,2
  While diagnosis remains challenging, the Pneumonia In Stroke ConsEnSus 
(PISCES) group recommended that “Stroke-Associated Pneumonia” (SAP) was the preferred 
diagnostic terminology covering the spectrum of lower respiratory tract infections 
complicating stroke within the first week and hospital acquired pneumonia (HAP) after 1 
week. 
3
 Further, acknowledging the limitations of current biomarkers and accessibility of 
microbiological samples, modified Centers for Disease Control and Prevention (CDC) 
criteria were proposed to aid clinicians and researchers in diagnosing SAP in non-ventilated 
patients. 
3 
Once SAP is suspected or diagnosed, however, use of antimicrobials vary and are either 
clinician dependant or guided by local policy for community acquired pneumonia (CAP) or 
HAP.
4
 Antibiotics used are often broad spectrum, without recourse to the microbiological 
etiology. The ability to better inform choice of antibiotic therapy in SAP, based on defined or 
likely microbial etiology, might lead to improved outcomes and enhanced antibiotic 
stewardship. Identifying microbiological etiology in non-ventilated stroke patients is 
challenging, due to the difficulties in obtaining direct samples from the lower respiratory tract  
(impaired cough and limited expectoration) and lack of applicable invasive procedures such 
as bronchoscopy in conscious stroke patients, in addition to reliance on sputum samples with 
the inherent risk of contamination from oropharyngeal commensal organisms.
5
 While 
bacterial colonisation of the oropharynx could potentially limit interpretation of positive 
sputum samples, poor diagnostic sensitivity of microbiological culture methods such as blood 
culture specimens (positive in <10%) 
6
 and pleural fluid aspirate limit their use. Most 
importantly, prior use of antibiotics hampers the sensitivity of microbiological techniques and 
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current stroke guidelines do not recommend early nonselective preventive antibiotic 
treatment. 
7,8 
As part of the ongoing PISCES collaboration, we sought to identify 
microbiological etiologies for pneumonia complicating stroke through a systematic review of 
available literature to help inform a planned consensus based approach for antibiotic 
treatment. 
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Methods 
A systematic literature review was undertaken in accordance with the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and Cochrane 
guidance. 
9, 10
 The authors declare that all supporting data are available within the article [and 
its online supplementary files]. 
Data sources and searches 
Searches were undertaken in MEDLINE (NIHL interface, 1946-1
st
 January 2017), EMBASE 
(NIHL interface, 1947-1
st
 January 2017) and Cochrane Central Register of Controlled Trials 
(Wiley interface, current issue) using pre-defined search criteria and terms (Online only 
Table I). Hand searching of reference lists for additional eligible articles was also carried out, 
and the members of PISCES group were invited to provide any other potentially eligible 
articles. Non-English full-text articles were translated and considered for inclusion if 
eligibility criteria were met.  
Study selection 
Published studies of hospitalized adults with ischemic stroke, intracerebral hemorrhage 
(ICH), or both, which identified any potential pathogen responsible for pneumonia 
complicating stroke, or which had used objective criteria for diagnosing pneumonia 
complicating stroke (but not reported causative organisms) were independently screened for 
eligibility by two reviewers (AKK and CJS), using the study title and abstract (Online Only 
Table II). For those studies which used objective criteria for pneumonia but which hadn’t 
reported causative pathogens, corresponding authors were contacted by e-mail for 
unpublished information on pathogens responsible for pneumonia if available. Lead or 
corresponding authors of studies under consideration were also contacted by e-mail to resolve 
any issues relating to assessment of eligibility or data extraction. Discrepancies relating to 
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eligibility or data extraction were resolved by a consensus discussion between the same two 
study investigators.
   
9 
 
Data Extraction 
Data were independently extracted by two reviewers (AKK and AV) and included study 
design, sample size, publication status and demographical data (year of study, country of 
study, clinical environment), stroke type (ischemic, ICH or both), interval from admission to 
diagnosis of pneumonia, frequency of pneumonia, criteria used for pneumonia diagnosis, 
mean age, mean National Institutes of Health Stroke Scale (NIHSS) score, cardiovascular risk 
profile, swallow screening, proportion of nil oral/tube-fed, type of culture specimen (sputum, 
blood culture, pleural or tracheal aspirate, serology), organisms identified and antibiotic 
usage (prophylactic and/or treatment). Reported data in the identified eligible publications 
were supplemented by contacting corresponding or lead authors where necessary. 
Study Outcomes  
The primary outcomes were the frequencies of the most commonly isolated microbial species 
among the included studies and the proportion of these organisms responsible for pneumonia. 
Secondary outcomes included: (1) The frequency of positive microbiological cultures and 
proportions of isolated organisms in positive cultures; (2) Relationships between microbial 
species and time interval from stroke onset to pneumonia; (3) Frequency of identified 
pathogens across different geographical regions. 
Risk of Bias and Quality Assessment 
We anticipated inclusion of both randomized controlled trials (RCTs) and non-randomized 
studies that had pneumonia as an outcome but were not primarily designed to identify 
microbiological etiologies. Hence, a formal statistical tool for assessing bias or the individual 
quality of the studies was not used as we were less concerned about the design or the effects 
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of interventions used in the individual studies for this review. However, as cultures for 
organisms would only be undertaken when pneumonia is suspected or diagnosed, 
heterogeneity among studies reporting pneumonia was assessed using random-effects model. 
Heterogeneity was quantified with the I
2 
statistic as reported in a previous study
1
. This 
measures the proportion of variation ascribed to excess heterogeneity beyond that anticipated 
by chance. Because of anticipated heterogeneity between studies reporting pneumonia, 
further quantitative meta-analysis on bacterial etiology was not undertaken. Summary 
statistics were instead undertaken to describe primary and secondary outcomes. A post-hoc, 
descriptive comparison of the frequency of pathogen species detected in pneumonia 
complicating stroke with other forms of pneumonia (e.g. CAP, HAP) was also undertaken. 
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Results 
Search Results 
A total of 6231 unique publications were identified by electronic searches and through the 
PISCES collaborators (Figure 1).Fifteen fully published studies were finally considered 
eligible for inclusion.
11-25 
Study and patient characteristics (Table 1, Online only Table III) 
The studies included retrospective (40%) or prospective (33%) observational studies and 
randomised trials (27%). 54% were European or North American studies; 46% were 
performed in South East Asia or Asia Pacific region. The majority of the studies were 
conducted on the acute stroke unit (72%). Other clinical environments included rehabilitation 
wards (7.5%) and intensive care units (15%). The mean age of the patients in individual 
studies ranged from 58 to 83 years. Baseline stroke severity (NIHSS) was reported in only 
73% of studies, with a mean ranging from 5 to 19. Three studies were RCTs of prophylactic 
antibiotics.
11,15,25
 Two studies were exclusively in nasogastric (NG) or percutaneous 
endoscopic gastrostomy (PEG) tube fed participants.
21,23
 33% of the studies included 
mechanically ventilated patients. Entry criteria to the studies varied widely, with only 1 study 
having the identification of microbiological etiology for pneumonia complicating stroke as a 
primary objective 
12
; 2 studies excluded patients on immunosuppressive medication, with 
prior malignancy, or other forms of immunosuppression prior to stroke. 
11, 22
  Other co-
morbidities and cardiovascular risk factor profiles were reported varyingly (Online only 
Table III). 
Diagnosis and frequency of pneumonia 
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Reported occurrence of pneumonia varied between studies (2% to 63%). Pooled frequency of 
reported pneumonia was 23% (95% CI 14%-34%; I
2
=99%, Figure 2). Substantial 
heterogeneity was noted even when adjusted to stroke subtype (ischemic stroke, I
2
=96%; 
mixed ischemic stroke and ICH, I
2
=99%) or geographical location (Asian studies, I
2
=97.4% 
and European or North American studies, I
2
=97.8%). When reported (60%), the majority of 
pneumonia occurred within 1 week of stroke (78%). The Centers for Disease Control and 
Prevention (CDC) criteria (45%) and ad hoc objective criteria (40%) were the most 
commonly used objective criteria to diagnose pneumonia.   
Microbiological etiology 
Sputum culture was most commonly used to identify pathogens either in isolation (40%), or 
in conjunction with tracheal aspirate (15%), and blood culture (20%). Reported frequency of 
positive culture data (15% to 88%) varied considerably.  Only 3 studies described the culture 
methods used to identify organisms. 
4, 13, 25 
No bacterial growths were reported in 2 studies 
(15% and 67%).
12, 25
  Identification of bacterial species in positive cultures varied between 
studies (Online only table IV). No pathogen was identified in every study, although 
Staphylococcus aureus was identified in positive cultures in 14 of 15 (93%) studies whilst 
Acinetobacter baumanii was identified in positive cultures in only 6 of 15 (40%) studies 
(Online only Table IV and Figure 3). Antibiotic susceptibility was not reported in the 
majority of studies; no studies reported any viral or other atypical organisms, although it was 
unclear if these were tested for. 
The proportions of microbial species associated with pneumonia also varied between studies. 
Overall, aerobic gram negative bacilli (AGNB, 38%) and gram positive cocci (GPC, 16%) 
were most frequently responsible for pneumonia; commonly isolated phenotypes (Table 2) 
included Enterobacteriaceae (21.8%: Klebsiella pneumoniae, 12.8% and Escherichia coli, 
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9%), S. aureus (10.1%), Pseudomonas aeruginosa (6%), Acinetobater baumanii (4.6%) and 
Streptococcus pneumoniae (3.5%).  Studies that included patients at relatively higher-risk  of 
pneumonia i.e. exclusively dysphagic patients or intensive care studies 
15,17,19,21
 were found to 
have a high proportion of AGNB and S. aureus, in comparison to lower risk studies 
(unselected stroke patients with ≤ 15 % ICH and/or mean NIHSS≤5, Table 1). It was not 
possible to explore relationships between timing of pneumonia or it’s severity with individual 
organisms because of insufficient data. 
We compared the frequencies of the 8 most commonly identified organisms in pneumonia 
complicating stroke with those of hospitalised CAP, VAP and HAP (Table 2) from recent 
reviews of literature (terminologies defined in Online only Table V). 
 26, 27, 28 ,29 
Geographical 
variations in bacterial etiology were observed in our study as seen as in the other reviews. In 
particular, gram-negative opportunistic pathogens such as P. aeruginosa and A. baumanii 
were more commonly isolated in South Asia or Asia Pacific regions (75% &100%) as 
opposed to Western Europe or the USA (28% & 0%). Several organisms were reported with 
comparable frequency (range) to VAP or HAP (e.g. K. pneumoniae, E. coli). S. pneumoniae, 
the organism most frequently identified in CAP, was detected less often in pneumonia 
complicating stroke. The organisms most often reported in HAP and VAP (S. aureus and P. 
aeruginosa) were also identified less frequently in pneumonia complicating stroke.  
Antibiotic usage 
Only 4 studies (24%) identified antibiotics used  to treat pneumonia complicating 
stroke.
13,15,20,25 
The antibiotic of choice was determined by local hospital policy and 
commonly included β-lactam (including ureidopenicillin and 2nd/3rd generation 
cephalosporins) antibiotics +/- β lactamase inhibitors and 2nd/3rd generation fluoroquinolones 
and was always initiated prior to obtaining antibiotic sensitivities. Only 1 study reported the 
   
14 
 
proportion of patients with pneumonia receiving antibiotics, the number of pneumonia 
episodes and functional outcomes following treatment with antibiotics.
25 
Discussion 
Pneumonia occurs most frequently during the first week after stroke (SAP) 
1, 3
 and may 
therefore include microbiological etiologies associated with hospitalized CAP or HAP. Our 
study suggests that AGNB (e.g. K. pneumoniae, E. coli and P. aeruginosa) and GPC (e.g. S. 
aureus and S. pneumoniae) were associated with the majority of pneumonia complicating 
stroke when cultures were sent. A recent review suggested that close to 80% of hospitalized 
CAP were caused by S. pneumoniae, Mycoplasma pneumoniae, Chlamydia pneumoniae and 
H. influenza.
26  
The same review found that approximately 50% of  HAP was caused by S. 
aureus and 35% by Pseudomonas species, Klebsiella species, Escherichia species, 
Acinetobacter species and Enterobacter species.
26 
The spectrum of identified organisms in 
our study appear to be more closely related to HAP than ventilator-associated pneumonia 
(VAP) or hospitalised CAP, although antibiotic susceptibilities were not reported in most of 
the included studies. Further, none of the included studies reported the results of 
investigations for viral or atypical pathogens, or even if they were done. Whilst our study is a 
comprehensive systematic literature research and collaboration within the PISCES group, our 
findings need to be interpreted with caution due to several inherent limitations. 
First, there was marked heterogeneity between the included studies, which likely contributed 
to the variation in identified organisms and their relative contributions to pneumonia. For 
example, studies undertaken in the critical care environment might yield a higher proportion 
of organisms overall because of access to more direct sampling (e.g. bronchoscopy or 
tracheal aspirate) and also more frequent etiologies due to organisms typical of HAP or VAP.  
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We could not identify any single factor that fully explained the high heterogeneity 
(I
2
=99%).   Although both stroke type and our prospective risk categorisation (Table 2) 
showed anticipated differences in pneumonia frequency, even within our ‘very high risk’ 
category frequency ranged from 14% to 63% (Figure 2), and heterogeneity remained 
extremely high (I
2
>90%) within each risk category. The asymmetry of the scatterplots seen in 
the funnel plot also reflects the high heterogeneity among studies which was not corrected 
even when subgroup analysis was undertaken with pneumonia risk stratification (Online only 
Figure I). 66% of the included studies in our review were deemed high or very high risk 
(Table I) for developing pneumonia reflecting the higher frequency of pneumonia seen in 
this review as opposed to a previous systematic review.
1
 Apart from patient selection, the 
overall high heterogeneity also reflects varying geographical location, different study designs, 
inclusion criteria, timing from stroke onset to sampling, and differences in standardised 
outcome definition for SAP. We were unable to differentiate pneumonia and causative 
pathogens for patients admitted from institutional environments such as nursing homes, 
which may have also contributed to heterogeneity. Stroke registries, not routinely expected to 
collect and maintain data on microbiological etiology, were also excluded unless specific 
mention was made regarding determining bacterial etiology, which could have contributed to 
selection bias and heterogeneity. The variation in approach to diagnosis of pneumonia 
complicating stroke is well-recognised,
1
 and may therefore influence the threshold for 
sending microbiological samples, contributing to verification bias. Second, only one of the 
studies was primarily designed to identify the microbial etiology of pneumonia complicating 
stroke, 
12 
 whilst the remaining studies collected microbiological data when available within 
the context of their individual study objectives.  It is reasonable to assume that the proportion 
of positive cultures could be higher if culture samples were sent systematically in all 
suspected cases of pneumonia. However, compared to other clinical settings (e.g. CAP or 
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VAP), consistently obtaining sputum samples in non-ventilated stroke patients is challenging 
and alternative strategies (e.g. bronchoscopy for VAP) are limited. Third, it was unclear 
amongst most studies as to when culture samples were sent in relation to onset of stroke and 
suspicion or diagnosis of pneumonia. Although the majority of pneumonia in our review 
occurred within a week of stroke symptom onset, it was not possible to further explore 
microbiological etiologies in relation to timing of pneumonia relative to stroke symptom 
onset. Whilst one could hypothesise that organisms commonly associated with CAP are most 
likely causal in early SAP (≤72 hours), and those associated with HAP causal in SAP beyond 
72h, we were unable to confirm or refute this finding because of limited data in the individual  
studies. Our observations of an apparent low yield of CAP organisms, and higher yield of 
HAP organisms could be at least in part due to sampling bias beyond 48-72h after stroke 
onset. Fourth, microbiological methods used to collect sputum samples, number of specimens 
sent when pneumonia was diagnosed, delays in analysing samples if any, and laboratory 
techniques used were inadequately reported. None of the studies used modern molecular 
based polymerase chain reaction (PCR) methods or urinary antigen testing (for organisms 
such as S. pneumoniae and Legionella pneumophilia).This may also contribute to differences 
in the observed frequencies of positive culture data and the apparent lack of atypical or viral 
etiologies. Interestingly, a recent study reviewing hospitalised patients identified close to 
22% of CAP inpatients had viral pathogens (most commonly rhinovirus, 9% and influenza, 
6%) implying that a viral etiology of SAP in at least some individuals may be possible.
30  
Finally, antibiotics preceding index stroke (especially for patients with chronic lung disease) 
may have influenced microbiological cultures. For example, in the PANTHERIS study, when 
sputum samples were analysed, 36% of samples were positive for organisms in the placebo 
group as opposed to 9% in the prophylactic antibiotic group.
15 
While the numbers are too 
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small to form further conclusions, prophylactic antibiotics administered to the participating 
stroke patients in the 3 RCTs may have affected frequency of identified organisms.  
It is important to emphasise the differences in frequency of pathogens identified in Asian 
compared to European or North American studies. For example, in a study of hospitalized 
CAP patients, S. pneumoniae appeared to have a lower frequency (13% v 26%) and 
Enterobacteriacae appeared to have a higher frequency (9% v 2.7%) in in Asian studies as 
compared to European studies.
5
 Similarly, while limited comparison was possible in our 
study, the frequency of certain nosocomial pathogens appeared to be higher in Asia or Asia-
Pacific regions (Online only Table IV) in keeping with higher prevalence of hospital-
acquired infection (15.5%) in comparison to Europe (7.1%) or the USA (4%). 
31  
However 
this incongruity may be as a result of  selection pressure on clinically relevant bacteria from 
differing prior antibiotic exposure of patients across continents, as well as possible 
implementation of pneumococcal vaccination programmes.  
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The scarce amount of available data on microbiological etiologies of pneumonia 
complicating stroke might also reflect the clinical routine, as suggested by a recent survey 
on German stroke units. 
32 
Treatment guidelines for pneumonia complicating stroke, 
nevertheless, should take into account these commonly isolated organisms and also 
consider local surveillance data, community pathogens and demographical variations, 
together with guidance from the WHO global strategy for containment of antimicrobial 
resistance 
33 
when recommendations are being made for prescribing empirical antibiotic 
regimens. Anaerobes, while not identified in our study, are commonly seen in the upper 
airway mixed with oral flora and in the stomach, are often thought to be responsible for 
aspiration pneumonia. However anaerobes are difficult to culture, and if aspiration is 
suspected, then broader spectrum antibiotics may be required.
28
  
The risk of contamination with oral flora, low diagnostic yield (30-40% sensitivity)
 
with 
current diagnostic methods
31
 and delay in producing a positive result (at least 24hrs-48hrs) 
often predisposes to initial broad spectrum antibiotic prescriptions. An ideal diagnostic 
method would be more timely and sensitive to identifying pathogens. PCR assays involving 
comprehensive molecular testing platforms significantly improve pathogen detection (87% v 
39%) in comparison to sputum culture (including viral pathogens) and provide results within 
24hrs, which may help in initiation of pathogen directed microbial therapy or a rapid de-
escalation of broad spectrum antibiotic therapy.
29
 However, validating such technology still 
depends on a reliable microbiological reference standard (sputum analysis) which may limit 
its potential utility in non-ventilated stroke patients.  
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Conclusion 
Our study demonstrates an evidence gap in appropriately designed studies that robustly 
identify microbiological etiologies in pneumonia complicating stroke. Although limited by 
small and heterogeneous study samples, this review suggests AGNB and GPC species are 
frequently associated with pneumonia complicating stroke. Difficulties in obtaining suitable 
sputum samples among non-ventilated stroke patients and poor sensitivity of current 
diagnostic methods often results in broad spectrum antibiotic prescriptions for pneumonia. 
Our study however supports the need for a consensus based approach to antibiotic initiation 
and further targeted antibiotic treatment trials for enhanced antibiotic stewardship. 
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Figure legends 
Figure 1: Flow diagram of systematic search methodology 
Figure 2: Forest plot of pneumonia frequency according to stroke subtype  
Fig 3: Proportion of studies identifying the eight most commonly isolated organisms 
 
 
 
 
 
 
 
 
 
 
 
 
   
21 
 
 
References 
1. Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, Di Napoli M, et al. How is 
pneumonia diagnosed in clinical stroke research? A systematic review and meta-analysis. 
Stroke. 2015; 46:1202-1209. 
2. Westendorp WF, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke 
infection: a systematic review and meta-analysis. BMC Neurology.2011; 11:110. 
3. Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of 
stroke-associated pneumonia: recommendations from the Pneumonia In Stroke ConsEnsuS 
Group. Stroke. 2015; 46:2335-2340. 
4. Harms H, Hoffmann S, Malzahn U, Ohlraun S, Heuschmann P, Meisel A. Decision-
making in the diagnosis and treatment of stroke-associated pneumonia. J Neurol Neurosurg 
Psychiatry. 2012; 83:1225-30.  
5. Peto L, Nadjm B, Horby P, Dieu Ngan TT, van Doorn Ra, Kinh NV, et al. The bacterial 
aetiology of adult community-acquired pneumonia in Asia: a systematic review. Trans R Soc 
Trop Med Hyg. 2014; 108: 326–337. 
6. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of 
blood cultures to the clinical management of adult patients admitted to the hospital with 
community-acquired pneumonia: a prospective study. Chest.2003; 123:1142–50. 
7. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, et al. Guidelines for 
the early management of adults with ischemic stroke: a guideline from the American 
Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, 
Cardiovascular Radiology and Intervention Council, and the Atherosclerotic 
Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary 
   
22 
 
Working Groups: the American Academy of Neurology affirms the value of this guideline as 
an educational tool for neurologists. Stroke.2007; 38:1655–711. 
8. Guidelines for management of ischaemic stroke and transient ischaemic attack. 
Cerebrovasc Dis. 2008; 25:457–507. 
9. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al, PRISMA-P 
Group. Preferred reporting items for systematic review and meta-analysis protocols 
(PRISMA-P): elaboration and explanation. BMJ. 2015; 349:g7647. 
10. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009. Available from 
www.cochrane-handbook.org (accessed 22
nd
 February 2017). 
11. Chamorro A, Horcajada JP, Obach V, Vargas M, Revilla M, Torres F, et al. The Early 
Systemic Prophylaxis of Infection After Stroke study: a randomised clinical trial. Stroke 
2005; 36: 1495–500. 
12. Hassan A, Khealani BA, Shafqat S, Aslam M, Salahuddin N, Syed N A, et al. Stroke-
associated pneumonia: microbiological data and outcome. Singapore Med J. 2006; 47: 204-
207. 
13. Vargas M, Horcajada JP, Obach V, Revilla M, Cervera A, Torres F, et al. Clinical 
consequences of infection in patients with acute stroke: is it prime time for further antibiotic 
trials? Stroke. 2006; 37: 461–65. 
14. Ros L, García M,  Prat J, González C, Gimeno C Albert A , et al. Factores predisponentes 
a la infección nosocomial en el ictus agudo y su influencia en la morbimortalidad. Med Clin 
(Barc). 2007; 128:441-7. 
15. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, et al. Preventive 
antibacterial therapy in acute ischemic stroke: a randomised controlled trial. PLoS One. 2008; 
3: e2158. 
   
23 
 
16. Sui R, Zhang L. Risk factors of stroke-associated pneumonia in Chinese patients. 
Neurological Research.2011; 33:508:514. 
17. Yeh S, Huang K, Wang T, Chen Y, Chen C, Tang S, et al. Dysphagia screening decreases 
pneumonia in acute stroke patients admitted to the stroke intensive care unit. Journal of the 
Neurological Sciences. 2011; 306:38–41. 
18. Fluri F, Morgenthaler NG, Mueller B, Christ-Crain M, Katan M. Copeptin, Procalcitonin 
and Routine Inflammatory Markers–Predictors of Infection after Stroke. PLoS ONE. 2012; 7: 
e48309. 
19. Chen L, Chang C, Hsu L , Tsai P, Chang S, Chang S, et al. Bacterial pneumonia 
following acute ischemic stroke. Journal of the Chinese Medical Association. 2013; 76:78-82 
20. Chen CM, Hsu HC, TsaiWS, Chang CH, Chen KH, Hong CZ. Infections in 
acute older stroke inpatients undergoing rehabilitation. Am J Phys Med Rehabil.2012; 
91:211-219. 
21. Satou Y, Oguro H, Murakami Y, Onoda K, Mitaki S, Hamada C, et al. Gastroesophageal 
Reflux during Enteral Feeding in Stroke Patients: A 24-hour Esophageal pH-monitoring 
Study. Journal of Stroke and Cerebrovascular Diseases. 2013; 22:185-189. 
22. Becker KJ, Dankwa D, Lee R, Schulze J, Zierath D, Tanzi P, et al.  Stroke, IL-1ra, 
IL1RN, Infection and Outcome. Neurocrit Care. 2014; 21:140–146. 
23. Warusevitane A, Karunatilake D, Sim J  Lally F, Roffe C. Safety and Effect of 
Metoclopramide to Prevent Pneumonia in Patients With Stroke Fed via Nasogastric Tubes 
Trial. Stroke. 2015; 46:454-460. 
24. Li Y, Song B, Fang H, Gao Y, Zhao L, Xu Y. External validation of the A2DS2 score to 
predict stroke-associated pneumonia in a Chinese Population: a prospective cohort study. 
PLoS ONE. 2014; 9: e109665. 
   
24 
 
25. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruyt ND, Bosboom HJ, et al for the 
PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic 
randomised open-label masked endpoint clinical trial. Lancet.2015; 385: 1519–26. 
26. Jones RN. Microbial Etiologies of Hospital-Acquired Bacterial Pneumonia and 
Ventilator-Associated Bacterial Pneumonia. Clinical Infectious Diseases. 2010; 51:S81–S87. 
27. Garau J, Calbo E. Community acquired pneumonia. Lancet.2008; 371:455-458 
28. Armstrong JR, Mosher BD. Aspiration Pneumonia After Stroke. Neurohospitalist. 
2011;1:85–93. 
29. Gadsby NJ, Russell CD, McHugh MP, Mark H, Morris AC, Laurenson IF, et al.  
Comprehensive Molecular Testing for Respiratory Pathogens in Community-Acquired 
Pneumonia. Clinical Infectious Diseases.2016; 62:817–23. 
30. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-
Acquired Pneumonia Requiring Hospitalization among U.S. Adults.  N Engl J Med. 
2015;373:415-27. 
31. Allegranzi B, Nejad SB, Combescure C, Graafmans W, Attar H, Donaldson L. Burden of 
endemic health-care-associated infection in developing countries: systematic review and 
meta-analysis. Lancet. 2011; 377:228–41. 
32. Harms H, Hoffmann S, Malzahn U, Ohlraun S, Heuschmann P, Meisel A, et al. Decision-
making in the diagnosis and treatment of stroke-associated pneumonia. J Neurol Neurosurg 
Psychiatry.2012; 83: 1225-1230. 
33. WHO (World Health Organization). 2015. Global Action Plan on Antimicrobial 
Resistance. Available on: http://www.who.int/antimicrobial-resistance/publications/global-
action-plan/en/ [accessed 10 November 2017].
   
25 
 
Table 1: Study characteristics 
First Author Year of 
recruitment 
Year Published Country Design Participants (n) Stroke Type Setting Mean 
Age (y) 
Male 
(%) 
Mean 
NIHSS 
Time to 
pneumonia 
diagnosis (d) 
Culture specimen Positive culture 
(%) 
Diagnostic 
criteria 
Pneumonia 
risk 
stratification 
Chamorro 2002-2004 2005 Spain 1 136 2 1 72.9 50 12 66% <7d sputum/tracheal 
aspirate 
45 2 2 
Hassan 1998-2001 2006 Pakistan 3 443 2 1 64 68 NR 67% <2d sputum/tracheal 
aspirate 
38 1 2 
Vargas 2001-2002 2006 Spain 2 229 2 1 72.3 51 9 ≤7d tracheal aspirate 41 2 2 
Ros 1998-1999 2007 Spain 2 258 2 1 74.9 48.8 NR NR blood  22 2 1 
Harms 2003-2006 2008 Germany 1 79 1 1 72.5 NR 16 ≤11d tracheal aspirate 45 1 3 
Sui  2000-2009 2011 China 3 1435 2 2 67.2 55.4 7 63% <3d sputum 38 1 2 
Yeh 2006-2007 2011 Taiwan 3 163 2 2 67.4 54 14 NR sputum 39 1 3 
Fluri 2006-2007 2012 Switzerland 2 383 1 1 71.4 57.7 5 ≤5d sputum/blood 15 1 1 
Chen  2002-2010 2012 Taiwan 3 341 2 3 73.4 48.6 NR NR sputum NR 3 2 
Chen  2006-2011 2013 Taiwan 3 495 1 4 80.3 72.5 15 53% <3d sputum/blood 75 1 2 
Satou NR 2013 Japan 2 16 1 1 83.2 NR NR NR NR 30 2 3* 
Becker  2005-2009 2014 USA 2 113 1 1 58 66 10 <15d sputum 88 2 1 
Warusevitane 2008-2011 2014 UK 1 60 2 1 77.5 37 19 94% <7d sputum 41 4 3* 
Li 2009-2011 2014 China 3 1279 1 1 63 NR NR NR           sputum NR 2 1 
Westendorp 2010-2014 2015 Netherlands 1 2538 2 1 73.5 57 5 NR sputum/blood  17 1 1 
Design-1= randomized controlled study, 2 =prospective observational study, 3 =retrospective study; Stroke type- 1=ischemic stroke, 2= ischemic stroke and intracerebral hemorrhage; Setting-
1 = Acute Stroke Unit (ASU); 2=Stroke Intensive Care; 3=ASU and rehabilitation unit; 4=Unclear; Criteria-1=Centers for Disease Control and Prevention Criteria, 2= Ad hoc Objective 
criteria, 3= Mann Criteria, 4=British Thoracic Society Criteria ; NIHSS=National Institutes of Health Stroke Scale; NR=not reported; Pneumonia risk stratification criteria-1=low risk 
(unselected stroke patients with ≤ 15% intracerebral haemorrhage, mean NIHSS ≤5) 2=high risk ( ≥15% intracerebral haemorrhage,NIHSS≥5), 3=very high risk ( exclusively dysphagia studies 
and/or tube-fed patients* ;studies involving  stroke patients in intensive care) 
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Table 2: Frequency of isolated organisms in pneumonia complicating stroke in comparison to other forms of pneumonia 
Identified organisms HAP (range, %) 
26 
VAP (range, %) 
26 
CAP (range, %) 
26,27,28 
Pneumonia complicating stroke 
(Weighted average with range, %) 
Gram Positive Cocci     
Staphylococcus aureus 26.6-36.5 19.5-31.9 3-14.1 10.1 (0-36.3) 
Streptococcal pneumoniae 1.8-3.2 <3 35-80 3.5 (0-10.7) 
Gram Negative Bacilli     
Klebsiella pneumoniae 8-10.5 6.6-10.2 3-6 12.8 (0-51) 
Escherichia coli 4.6-10.1 3-5 6-12 9 (0-21.7) 
Pseudomonas aeruginosa 19-22.4 21.4-26.6 2.8-9 6 (0-11.7) 
Acinetobacter baumanii 4.4-13.3 14.3 3-14.3 4.6 (0-22.9) 
Haemophilus influenzae 1.3-3.7 NR 5-40 1.9 (0-11.5) 
Enterobacter cloacae 6.3-8.5 6-8.8 NR 1.7 (0-10) 
HAP=hospital acquired pneumonia, VAP =ventilator associated pneumonia, CAP=community acquired pneumonia, NR= not recorded
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Records identified through database searching (N) 
Medline 2945 
Embase 7480 
CINAHL          5083 
Cochrane Library        281 
 
 
 
 
 
 
 
 
(n =   ) 
Records after duplicates removed  
(N=6231) 
Screening criteria 
a) English or non-English published studies/ 
abstracts 
b) Ischemic stroke or intracerebral 
hemorrhage 
c) Pneumonia complicating stroke identified 
 
 
Records screened
N=983 
 
 
Records excluded 
N=  936 
 
Eligibility criteria 
a) Age ≥ 18years   
b) Inpatients with ischemic stroke, 
intracerebral haemorrhage or both  
c) Fully published/completed prospective 
or retrospective observational studies, 
quasi-experimental or randomised trials 
d) Frequency of pneumonia complicating 
acute stroke identified 
e) Objective criteria used to diagnose 
pneumonia complicating stroke  
            and/or 
Microbiological etiologies identified for 
pneumonia complicating stroke 
 
Full-text articles/abstracts 
assessed for eligibility  
N=47 
 
Full-text articles/abstracts 
excluded with reasons 
N= 32 
 
Studies included for qualitative analysis 
N=15 
 
References; Citations; 
PISCES collaboration 
N=13 
 
 
 
 
 
 
 
(n =   ) 
Microbiological etiology not collected=25 
Oral microbiology (colonisation) only=2 
Infection preceding stroke included=1 
Predominantly intubated/ventilated 
and/or post-operative stroke patients =4 
 
Animal studies=10 
Non-stroke studies=163 
Frequency of pneumonia not 
identified=763 
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Fig. 2 
  
0 10 20 30 40 50 60 70 80 90
Author Participant (n) Proportion (%) 
Satou 16 63 
Harms 79 14 
Becker  113 8 
Fluri 383 5 
Chen  495 10 
Li 1279 24 
Pooled (Ischemic) 16 
Warusevitane 60 57 
Chamorro 136 20 
Yeh 163 51 
Vargas 229 18 
Ros 258 23 
Chen  341 30 
Hassan 443 23 
Sui  1435 38 
Westendorp 2538 2 
Pooled (Mixed stroke) 27 
Total (I2=99%)  23 
I2=96% 
I2=99% 
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Online only Table I: Search Terms 
Search Areas Thesaurus terms Free Text Terms 
MEDLINE 
 
Subject Search in MESH: exp 
*Cerebrovascular disorders/; exp 
*Pneumonia/; 
[Limit to: Publication Year 1946-2016] 
Stroke*,Pneumonia*, “respiratory 
tract infection*”, “chest infection*” 
 
 
[Limit to: Publication Year 1946-
2016] 
EMBASE 
 
Subject Search on EMTREE: exp 
*Cerebrovascular disease/ exp 
*Pneumonia/;  
[Limit to: Publication Year 1901-2016] 
Stroke*, Pneumonia*, “respiratory 
tract infection*”, “chest infection*” 
 
 [Limit to: Publication Year 1901-
2016] 
 
CINAHL 
Subject Search: exp *Cerebrovascular 
disorders/; exp *Pneumonia/; 
[Limit to: Publication Year 1946-2016] 
Stroke*,Pneumonia*, “respiratory 
tract infection*”, “chest infection*” 
[Limit to: Publication Year 1901 to 
2016] 
Cochrane Cochrane Central 
Register of Controlled Trials 
[Limit to: Publication Year 1980-2016] All text: “stroke”  “pneumonia”  
Publication Year from 1980 to 2016, 
in Cochrane Reviews (Protocols only), 
Trials and Methods Studies (Word 
variations have been searched) 
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Online only Table II: Eligibility criteria 
Inclusion criteria: 
Age ≥ 18years   
Fully published studies or abstracts 
English or non-English language 
Inpatients with ischemic stroke, intracerebral haemorrhage, or both 
Randomized (RCT’s) and other controlled trials, including cluster RCTs, controlled (non-
randomized) clinical trials (CCTs) or cluster trials, prospective comparative cohort studies, 
retrospective observational studies, case-control or nested case-control studies. 
Incidence or prevalence of pneumonia following admission with stroke reported 
Possible microbiological etiologies identified as responsible for pneumonia complicating 
stroke OR objective criteria used for diagnosing pneumonia 
Exclusion criteria: 
Age<18years 
Exclusively intubated and mechanically ventilated patients 
Exclusively pneumonia preceding index stroke 
Case reports  
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Online only Table III: Patient characteristics 
Author NG or PEG 
feeding (%) 
Prophylactic 
antibiotics 
                                                                                                  Co-morbidities (%) MV (%) 
   COPD/other lung pathology Immunosuppression  Previous 
Stroke 
Smoking history Heart disease AF HTN DM  
Chamorro1  48 Yes 9.5 Excluded 17.6 16.9 12.5 NR 63.2 22.8 0 
Hassan2 NR No NR NR NR NR NR NR NR NR 0 
Vargas3 42 NR 10 4.3 16.1 16 NR NR 60 19 0 
Ros4 NR NR NR NR 12.4 NR 13.2 12.8 63.2 35.3 0 
Harms5 66 Yes 7.5 8.8 11.4 11.4 37.2 34.1 64.5 31.6 8.8 
Sui6 47  NR NR NR NR 49 32 NR NR 44  2.2 
Yeh7 73 No NR NR NR NR NR NR NR NR 12.2 
Fluri8 NR NR NR NR NR NR 34 19.4 80 19.3 0 
Chen9 58 NR NR NR NR NR NR NR 82 39 0.3  
Chen10  NR NR 25.5* 14* 31.4* 43* 27.5* NR 70.6
*  
29.4*  23.5* 
Satou11 100 NR NR NR NR NR NR NR NR NR NR 
Becker 12 NR No NR Excluded 35.3 37 24 NR 53.1 24 NR 
Warusevitane13 100 No 16 NR NR NR NR 60 66 28 0 
Li14 NR NR NR NR NR 40 NR NR 74 20 NR 
Westendorp15 NR Yes 8.2 17.3 32.5 24.4 13 15.4 55.2 19.7 0 
NR=Not Reported, COPD=Chronic Obstructive Pulmonary Disease, AF=Atrial fibrillation, HTN=hypertension, DM=diabetes mellitus, MV=mechanical ventilation,* with pneumonia 
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Online only Table IV: The eight most commonly isolated organisms in positive cultures (%) in the included studies 
 
                                       European or North American Studies                               Asian Studies 
  Chamorro Vargas Ros Harms Fluri Becker Warusevitane Westendorp  Sui Yeh Li Satou Hassan Chen Chen 
GRAM POSITIVE COCCI                 
Staphylococcus aureus 11 × 5 36.3 5 22.2 11.7 1.7  9.3 19.2 6.8 20 11.7 24.1 1.9 
Streptococcal pneumoniae 3.7 2.4 × 9 × × × 1.7  0.5 1.2 10.7 × 3.9 2.8 1 
GRAM NEGATIVE BACILLI                 
Klebsiella pneumoniae × × 5 × × 11.1 11.7 ×  8.8 51 18.2 10 3.9 15.4 23.5 
Escherichia coli × 7.3 × × × × 5.8 ×  7.7 9 21.7 × 1.9 2.8 10 
Enterobacter cloacae × 7.3 1.7 × × × 5.8 ×  × 9.6 × × 1.9 3.8 10 
Pseudomonas aeruginosa × 2.4 × × × 11.1 × ×  6.6 4.8 8.2 × 11.7 6.7 3.9 
Haemophilus influenzae 3.7 21.9 × × 5 11.1 × ×  6.6 × × × 3.9 11.5 7.8 
Acinetobacter baumanii × × × × × × × ×  1.4 22.9 8.4 × 3.9 6.7 7.8 
For each study, data represent % of positive cultures due to the microbial species listed. X indicates not identified 
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Online only Table V: Definition of pneumonia terminologies 
Types of pneumonia Definition 
Hospitalized community acquired pneumonia 
(CAP)
16 
Pneumonia  i.e. symptoms and signs consistent with 
an acute lower respiratory tract infection in the 
community,  associated with new radiographic 
shadowing for which there is no other explanation  
and needing hospital admission 
Hospital acquired pneumonia (HAP)
17
 Pneumonia in a hospitalised patient > 48-72 hours 
after admission, without any incubation period 
Ventilator-associated pneumonia (VAP)
17
 Pneumonia in a patient occurring > 48-72 hours 
after intubation 
Stroke associated pneumonia (SAP)
18
 Pneumonia in a patient ≤7 days from stroke symptom 
onset (HAP after this period); Early SAP< 72hrs, late 
SAP>72hrs 
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Online only Figure I: Funnel Plot 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          Proportion of pneumonia  
Scatterplots representing 
individual studies 
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